Ibis Sánchez-Serrano is a world-leading expert on global healthcare, pharmaceutical innovation, and translational science policy. He is a member of the Editorial Board of the journal Gender & the Genome and has written two books, The World's Health Care Crisis: From the Laboratory Bench to the Patient's Bedside (Elsevier, 2011) and The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care (Elsevier, 2019). Mr. Sánchez-Serrano has built a reputation amongst important international government bodies as an expert on the world's healthcare crisis and the relevant solutions. He's a frequent speaker on global health care and pharmaceutical development and received international recognitions for his work on global health care, including a "Fulbright Recognition Award” and media coverage including CNN, C-SPAN, UNIVISION, EFE Agency, Deutsche Presse Agentur. His research interests include Health Care, Pharmaceuticals, Biotechnology, Public Health, Academia-Industry Relationship, Drug Discovery and Development, Organization and Management of R&D.

Part I1. Introduction: the remarkable success story of the development of bortezomib2. Lessons from the development of bortezomib: the Core Model

Part II3. The "Core”: when innovation meets leadership 4. "The Bridge”: collaboration is the best catalyst to success5. "The Periphery”: the efficient use of underused societal resources

Part III6. Biopharmaceutical intellectual property, financial interests, and the Core Model7. Global health care crisis, the pharmaceutical industry, and the Core Model8. The Core Model, innovation, economic growth, development, and policy-making

Part IV9. Conclusion: the Core Model: a novel economic theory10. Epilogue: the Core Model and other industries

The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industry´s productivity problems and address important global health care and economic issues.

This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes.